2022
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki S, Bjork J, Blow F, Brenner L, Chen P, Desai S, Dieperink E, Fears S, Fuller M, Goodman C, Graham D, Haas G, Hamner M, Helstrom A, Hurley R, Icardi M, Jurjus G, Kilbourne A, Kreyenbuhl J, Lache D, Lieske S, Lynch J, Meyer L, Montalvo C, Muralidhar S, Ostacher M, Paschall G, Pfeiffer P, Prieto S, Przygodzki R, Ranganathan M, Rodriguez-Suarez M, Roggenkamp H, Schichman S, Schneeweis J, Simonetti J, Steinhauer S, Suppes T, Umbert M, Vassy J, Voora D, Wiechers I, Wood A. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA 2022, 328: 151-161. PMID: 35819423, PMCID: PMC9277497, DOI: 10.1001/jama.2022.9805.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPatient Health Questionnaire-9Usual care groupUsual carePharmacogenomic testingDrug-gene interactionsRemission rateMedication selectionCare groupDepressive disorderVeterans Affairs Medical CenterActive substance use disorderCo-primary outcomesPrescription of medicationsBetter clinical outcomesProportion of prescriptionsRemission of symptomsSubstance use disordersEligible patientsWeek 24Effective antidepressantSingle antidepressantClinical outcomesInitial treatmentQuestionnaire-9
2014
Posttreatment Effects of Topiramate Treatment for Heavy Drinking
Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcohol Clinical And Experimental Research 2014, 38: 3017-3023. PMID: 25581656, PMCID: PMC4293099, DOI: 10.1111/acer.12578.Peer-Reviewed Original ResearchConceptsPercent days abstinentHeavy drinking daysTopiramate treatmentHeavy drinkingDrinking daysHeavy drinkersAllele homozygotesPlacebo-controlled trialEffects of topiramateEnd of treatmentPersistent therapeutic effectKainate receptor subunitsHigher percent days abstinentTherapeutic effectTreatment goalsAlcohol-related problemsAllele carriersDays abstinentAbstinent daysPosttreatment effectsReceptor subunitsReduced drinkingSingle nucleotide polymorphismsStatistical significanceComplete dataPharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2014, 23: 288-293. PMID: 24724887, PMCID: PMC4600600, DOI: 10.1111/j.1521-0391.2014.12102.x.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DeterrentsAlcoholismDiagnosis, Dual (Psychiatry)DisulfiramDopamine beta-HydroxylaseDrug Therapy, CombinationFemaleGenotypeHeterozygoteHumansMaleMental DisordersMiddle AgedNaltrexoneNarcotic AntagonistsPolymorphism, Single NucleotideReceptors, Opioid, muTreatment OutcomeVeteransWhite PeopleConceptsAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsOPRM1 rs1799971Favorable responseMore abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinkingTopiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. American Journal Of Psychiatry 2014, 171: 445-452. PMID: 24525690, PMCID: PMC3997125, DOI: 10.1176/appi.ajp.2013.13081014.Peer-Reviewed Original ResearchConceptsHeavy drinking daysHeavy drinkersTopiramate treatmentDaily doseHeavy drinkingTopiramate's effectsDrinking daysAbstinent daysUse of topiramateMaximal daily doseWeeks of treatmentC allele homozygotesPersonalized treatment optionsEnzyme γ-glutamyl transpeptidasePlacebo groupΓ-glutamyl transpeptidaseTreatment optionsTreatment completionPharmacogenetic findingsTreatment goalsAlcohol-related problemsKainate receptorsTreatment groupsBrief counselingAlcohol dependence
2011
GABRA2 and KIBRA genotypes predict early relapse to substance use
Bauer LO, Covault J, Gelernter J. GABRA2 and KIBRA genotypes predict early relapse to substance use. Drug And Alcohol Dependence 2011, 123: 154-159. PMID: 22129841, PMCID: PMC3294190, DOI: 10.1016/j.drugalcdep.2011.11.004.Peer-Reviewed Original ResearchConceptsMonths of abstinenceDrug use problemsCognitive controlContribution of ageAbstinence violationDrug abuse problemsKIBRA genotypeUse problemsDepression symptomsDrug involvementSubstance useAbuse problemsTreatment settingsDrug useKIBRARisk of relapseFuture studiesGABRA2AbstinenceSmall samplesEthnic groupsANKK1Younger age
2009
The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation
Zuo L, Luo X, Krystal JH, Cramer J, Charney DS, Gelernter J. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenetics And Genomics 2009, 19: 437-446. PMID: 19369910, PMCID: PMC2857717, DOI: 10.1097/fpc.0b013e32832b9cfc.Peer-Reviewed Original Research
2008
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Mäkelä R, Kranzler HR. Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. Alcohol Clinical And Experimental Research 2008, 32: 1159-1166. PMID: 18537939, PMCID: PMC2950972, DOI: 10.1111/j.1530-0277.2008.00735.x.Peer-Reviewed Original ResearchConceptsOpioid receptor geneSingle nucleotide polymorphismsTherapeutic effectReceptor geneHeavy drinkingOpioid antagonist nalmefenePlacebo-controlled trialKappa-opioid receptorsNaltrexone treatment responseHeavy drinking daysReceptor gene polymorphismsOpioid receptor gene polymorphismsAsn40Asp polymorphismNalmefene treatmentPolymorphic variationAntagonist treatmentMedication responseTreatment responsePharmacogenetic analysisReceptor gene variationDrinking daysNalmefeneGene polymorphismsHeavy drinkersConflicting results
2007
Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects
Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR. Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects. Alcohol Clinical And Experimental Research 2007, 31: 1780-1787. PMID: 17949392, PMCID: PMC3169387, DOI: 10.1111/j.1530-0277.2007.00517.x.Peer-Reviewed Original ResearchConceptsTwelve-step facilitationMotivational enhancement therapyCognitive behavioral therapyPsychosocial treatmentsSingle nucleotide polymorphismsAlcohol dependenceGABRA2 single nucleotide polymorphismsMulti-center randomized clinical trialHeavy drinkingRandomized clinical trialsLow-risk allelesPost-treatment periodPresent studyClinical trialsLower riskEuropean-American subjectsAlcoholism treatmentBehavioral therapyGABRA2 genotypeGABRA2 geneEnhancement therapyLower daily probabilityDrinking outcomesGenetic vulnerabilityPrevious studiesOpioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study
Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, Group T. Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcohol Clinical And Experimental Research 2007, 31: 555-563. PMID: 17374034, DOI: 10.1111/j.1530-0277.2007.00339.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismConfidence IntervalsDNADouble-Blind MethodExonsFemaleGenetic VariationGenotypeHumansLinear ModelsLogistic ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOdds RatioProportional Hazards ModelsPsychiatric Status Rating ScalesReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muSmokingTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAlcohol dependenceOpioid receptorsTreatment responseVA Cooperative StudyRate of relapsePredictors of responseAlcohol-dependent male subjectsMu-opioid receptorsKappa-opioid receptorsCourse of treatmentShort-term treatmentReceptor gene variantsOpioid receptor geneAsn40Asp polymorphismAvailable medicationsNaltrexone treatmentSpecific pharmacotherapyPretreatment numberDrug naltrexoneNaltrexoneMale subjectsCooperative StudyRelapseHeavy drinkingIndividual single nucleotide polymorphisms
1994
Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine
Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine. JAMA Psychiatry 1994, 51: 912-917. PMID: 7944879, DOI: 10.1001/archpsyc.1994.03950110072009.Peer-Reviewed Original ResearchConceptsClinical responseTherapeutic effectAtypical antipsychotic drug clozapineClozapine's therapeutic effectsTreatment-refractory schizophreniaPathophysiology of schizophreniaAntipsychotic drug clozapineD4 dopamine receptorsDRD4 allelesPutative third cytoplasmic loopSchizoaffective patientsTherapeutic responseTherapy variesDopamine receptorsSchizoaffective subjectsTreatment responseThird cytoplasmic loopDrug clozapineClozapineDopamine receptor geneSchizoaffective disorderD4 receptorsPolymerase chain reaction amplificationReceptor allelesChain reaction amplification